Neuronal T-type alpha 1H calcium channels induce neuritogenesis and expression of high-voltage-activated calcium channels in the NG108-15 cell line.
Neuronal differentiation involves both morphological and electrophysiological changes, which depend on calcium influx. Voltage-gated calcium channels (VGCCs) represent a major route for calcium entry into neurons. The recently cloned low-voltage-activated T-type calcium channels (T-channels) are the first class of VGCCs functionally expressed in most developing neurons, as well as in neuroblastoma cell lines, but their roles in neuronal development are yet unknown. Here, we document the part played by T-channels in neuronal differentiation. Using NG108-15, a cell line that recapitulates early steps of neuronal differentiation, we demonstrate that blocking T-currents by nickel, mibefradil, or the endogenous cannabinoid anandamide prevents neuritogenesis without affecting neurite outgrowth. Similar results were obtained using antisense oligodeoxynucleotides directed against the alpha1H T-channel subunit. Furthermore, we describe that inhibition of alpha1H T-channel activity impairs concomitantly, but independently, both high-voltage-activated calcium channel expression and neuritogenesis, providing strong evidence for a dual role of T-channels in both morphological and electrical changes at early stages of neuronal differentiation.
Chemin
Jean
J
Institut de Génétique Humaine, Centre National de la Recherche Scientifique, Unité Propre de Recherche 1142, F-34396 Montpellier cedex 05, France.
Nargeot
Joël
J
Lory
Philippe
P
D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology; D001973:Bromodeoxyuridine; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D020747:Calcium Channels, T-Type / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D002186:Cannabinoids / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D002460:Cell Line; D063388:Endocannabinoids; D020748:Mibefradil / Q000494:pharmacology; D051379:Mice; D016501:Neurites / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D009532:Nickel / Q000494:pharmacology; D020319:Oligodeoxyribonucleotides, Antisense / Q000494:pharmacology; D018408:Patch-Clamp Techniques; D053284:Polyunsaturated Alkamides; D021122:Protein Subunits; D012333:RNA, Messenger / Q000037:antagonists & inhibitors / Q000378:metabolism; D051381:Rats
D001095:Arachidonic Acids; D002121:Calcium Channel Blockers; D020747:Calcium Channels, T-Type; D002186:Cannabinoids; D063388:Endocannabinoids; D020319:Oligodeoxyribonucleotides, Antisense; D053284:Polyunsaturated Alkamides; D021122:Protein Subunits; D012333:RNA, Messenger; D020748:Mibefradil; D009532:Nickel; D001973:Bromodeoxyuridine; D002118:Calcium; C078814:anandamide